What is HC Wainwright’s Estimate for AMLX FY2030 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Stock analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for Amylyx Pharmaceuticals in a note issued to investors on Monday, January 26th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of $1.70 per share for the year. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share.

AMLX has been the subject of several other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Monday, December 29th. Citigroup lifted their price target on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Lifesci Capital raised Amylyx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 27th. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, December 20th. Finally, Bank of America lifted their target price on Amylyx Pharmaceuticals from $14.00 to $16.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amylyx Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $17.25.

Amylyx Pharmaceuticals Trading Down 6.2%

Shares of Amylyx Pharmaceuticals stock opened at $14.51 on Tuesday. The company has a market cap of $1.59 billion, a PE ratio of -8.06 and a beta of -0.31. The company has a 50 day moving average of $13.45 and a 200-day moving average of $12.07. Amylyx Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of hedge funds have recently modified their holdings of AMLX. Millennium Management LLC raised its holdings in Amylyx Pharmaceuticals by 418.6% during the 1st quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after purchasing an additional 2,487,617 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Amylyx Pharmaceuticals by 7.7% during the first quarter. Goldman Sachs Group Inc. now owns 2,002,961 shares of the company’s stock worth $7,090,000 after buying an additional 143,065 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth $1,541,000. Los Angeles Capital Management LLC bought a new position in Amylyx Pharmaceuticals during the second quarter worth $149,000. Finally, Acadian Asset Management LLC lifted its holdings in Amylyx Pharmaceuticals by 135.1% in the second quarter. Acadian Asset Management LLC now owns 569,083 shares of the company’s stock valued at $3,645,000 after buying an additional 326,976 shares during the period. Institutional investors and hedge funds own 95.84% of the company’s stock.

Insider Transactions at Amylyx Pharmaceuticals

In other news, Director Karen Firestone purchased 8,100 shares of the business’s stock in a transaction dated Tuesday, December 23rd. The shares were purchased at an average cost of $12.45 per share, with a total value of $100,845.00. Following the completion of the purchase, the director owned 63,100 shares of the company’s stock, valued at $785,595. This trade represents a 14.73% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Joshua B. Cohen sold 136,193 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $13.59, for a total value of $1,850,862.87. Following the completion of the transaction, the chief executive officer directly owned 3,378,621 shares of the company’s stock, valued at $45,915,459.39. This represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 157,783 shares of company stock valued at $2,122,808. 12.30% of the stock is currently owned by corporate insiders.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.